Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jul;11(7):878-888.
doi: 10.1002/cpdd.1107. Epub 2022 May 20.

Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study

Ziad Hussein  1 , Oneeb Majid  1 , Peter Boyd  1 , Jagadeesh Aluri  2 , Leock Y Ngo  2 , Larisa Reyderman  2
Affiliations
Clinical Trial

Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study

Ziad Hussein et al. Clin Pharmacol Drug Dev. 2022 Jul.

Abstract

Intravenous (IV) drug administration enables treatment of epilepsy when oral administration is temporarily not feasible. Perampanel is a once-daily antiseizure medication currently available as oral formulations. Study 050 (NCT03376997) was an open-label, randomized, single-dose, crossover study to evaluate the interchangeability of oral and IV perampanel in healthy subjects (N = 48). Bioequivalence of single 12-mg doses of IV (30-, 60-, or 90-minute infusion) and oral perampanel, ≥6 weeks apart, was assessed. Analyses indicated bioequivalence of area under the plasma concentration-time curve extrapolated to infinity for 30- and 60-minute IV infusions and oral perampanel doses (geometric mean ratio [90% confidence interval], 0.93 [0.84-1.02] and 1.03 [0.97-1.09], respectively); however, IV maximum observed drug concentration (Cmax ) values were 1.35- to 1.61-fold higher than Cmax . Simulated plasma concentration-time profiles using pooled pharmacokinetic data further supported oral and IV perampanel interchangeability in two scenarios: 12-mg per day IV dosing during a temporary 7-day switch from oral steady-state maintenance therapy, and treatment initiation with 2-mg perampanel. Thirty-four (70.8%) subjects experienced treatment-related adverse events. The IV perampanel safety profile was similar to that of oral perampanel without new safety concerns. Perampanel IV infusions may be a suitable temporary alternative to oral perampanel for treatment maintenance and/or initiation.

Keywords: antiseizure medication; bioavailability/bioequivalence; epilepsy; intravenous; perampanel.

PubMed Disclaimer

Conflict of interest statement

Z.H., O.M., and P.B. are employees of Eisai Europe Ltd. J.A., L.Y.N., and L.R. are employees of Eisai Inc. Medical writing support, under the direction of the authors, was provided by Laura George, PhD, on behalf of CMC AFFINITY, McCann Health Medical Communications, funded by Eisai Inc., in accordance with Good Publication Practice (GPP3) guidelines.

Figures

Figure 1
Figure 1
Clinical study design. EOS, end of study; IV, intravenous; R, randomization.
Figure 2
Figure 2
Mean (SD) plasma concentration–time profiles of perampanel following single 12‐mg IV infusions (30, 60, and 90 minutes) and 12‐mg oral tablet administration over (A) 4 hours and (B, C) 72 hours after initiation of dosing. IV, intravenous; SD, standard deviation.
Figure 3
Figure 3
Simulated perampanel plasma concentration–time profiles following switching from oral steady state on day 28 to first perampanel 12‐mg IV infusion on day 29, seventh perampanel 12‐mg IV infusion on day 35, and first day of oral tablet restart on day 36 for (A) 30‐minute IV infusions, (B) 60‐minute IV infusions, and (C) 90‐minute IV infusions, all vs oral tablet at steady state on day 28. IV, intravenous.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) . Epilepsy Key Facts. https://www.who.int/news‐room/fact‐sheets/detail/epilepsy. Accessed October 5, 2021.
    1. GBD 2016 Stroke Collaborators . Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):439‐458. - PMC - PubMed
    1. Harden C, Tomson T, Gloss D, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Curr. 2017;17(3):180‐187. - PMC - PubMed
    1. Hesdorffer DC, Tomson T, Benn E, et al. Do antiepileptic drugs or generalized tonic‐clonic seizure frequency increase SUDEP risk? A combined analysis. Epilepsia. 2012;53(2):249‐252. - PubMed
    1. Asadi‐Pooya AA, Nikseresht A, Yaghoubi E, Nei M. Physical injuries in patients with epilepsy and their associated risk factors. Seizure. 2012;21(3):165‐168. - PubMed

Publication types

Associated data